Product Description
CD45 Antibody [PTPRC/1461] | 33-658 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: Human B lymphocytes were used as the immunogen for the CD45 antibody.
Research Area: Cancer, Immunology, Neuroscience, Signal Transduction
Tested Application: WB, Flow, IHC-P, IF
Application: Flow Cytometry: 0.5-1 ug/million cells
Immunofluorescence: 0.5-1 ug/ml
Immunohistology (FFPE) : 0.5-1.0 ug/ml for 30 minutes at RT
Due to variation in protocol and secondary antibody used, the CD45 antibody may need to be titered for optimal performance.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: PTPRC/1461
Isotype: IgG2a, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: Receptor-type tyrosine-protein phosphatase C, Leukocyte common antigen, L-CA, T200, CD45, PTPRC, CD45
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: CD45R, also designated CD45 and PTPRC, has been identified as a transmembrane glycoprotein, broadly expressed among hematopoietic cells. Multiple isoforms of CD45R are distributed throughout the immune system according to cell type. These isoforms arise because of alternative splicing of exons 4, 5, and 6. The corresponding protein domains are characterized by the binding of monoclonal antibodies specific for CD45RA (exon 4) , CD45RB (exon 5) , CD45RC (exon 6) and CD45RO (exons 4 to 6 spliced out) . The variation in these isoforms is localized to the extracellular domain of CD45R, while the intracellular domain is conserved. CD45R functions as a phosphor-tyrosine phosphatase. Antibody to CD45 is useful in differential diagnosis of lymphoid tumors from non-hematopoietic undifferentiated neoplasms.